Schizophrenia Clinical Trial
Official title:
Intramuscular Clozapine in the Management of Aggression in Schizophrenic Patients
Aggressive, persistent aggression and impulsive behavior are frequently observed in
schizophrenic patients. According to some researchers "more than 50% of all psychiatric
patients and 10% of schizophrenic patients show aggressive symptoms varying from threatening
behavior and agitation to assault"(1). It is a common cause of psychiatric admission and is
a therapeutic issue. The treatment of these symptoms is a clinical problem for both patients
and staff. Violent behavior, a major detrimental factor in stigmatization of the mentally
ill, also poses physical danger for the patients themselves. Current pharmacotherapy of
pathologic aggression involves the use of multiple agents (typical and atypical
antipsychotics, benzodiazepines, mood stabilizers, beta-blockers, antiandrogenic hormones,
and selective serotonin reuptake inhibitors) on empiric basis, with varying degrees of
response (2-6). Unfortunately, these approaches lead to numerous side effects. Poor or
noncompliance with pharmacotherapy makes it difficult to choose the appropriate preparation.
Currently, typical neuroleptics are still the first choice in treating acute aggressive
symptoms, while risperidone and olanzapine could be alternatives (5-7). Typical depot
neuroleptics should be considered in cases where medication compliance is a problem. Most
clinical information on treating of aggression has been collected about atypical
neuroleptics, particularly regarding clozapine.
Clozapine is indicated in psychotic state and/or in drug-resistant schizophrenic patients.
According to the FDA - it is the drug of choice in suicidal and aggressive patients, due-to
psychotic state. It was found helpful in nearly 30% of resistant schizophrenic patients.
Concerning the parenteral administration of clozapine - very little data is available today.
This study aims to investigate efficacy and safety (psychopathology, and side effects) of
parenteral clozapine in treatment of aggressive behavior in schizophrenic patients in a
double-blind trial.
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
| Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
| Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
| Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
| Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
| Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
| Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
| Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
| Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
| Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
| Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
| Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
| Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
| Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
| Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
| Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
| Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |